18080-67-6
基本信息
2,3-BIS(BROMOMETHYL)QUINOXALINE 1,4-DIOXIDE
Quinoxaline, 2,3-bis(bromomethyl)-, 1,4-dioxide
2,3-bis(broMoMethyl)-1-oxoquinoxalin-1-iuM-4(1H)-olate
物理化學性質(zhì)
報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
2024/11/08 | HY-116090 | 1,4-二氧代-2,3-二溴甲基喹啉 Conoidin A | 18080-67-6 | 25mg | 500元 |
2024/11/08 | HY-116090 | 1,4-二氧代-2,3-二溴甲基喹啉 Conoidin A | 18080-67-6 | 10mM * 1mLin DMSO | 550元 |
2024/11/08 | HY-116090 | 1,4-二氧代-2,3-二溴甲基喹啉 Conoidin A | 18080-67-6 | 100mg | 1000元 |
常見問題列表
IC50: 23 μM ( T. gondii enzyme peroxiredoxin II (TgPrxII))
Peroxiredoxins are a widely conserved family of enzymes that function in antioxidant defense and signal transduction. And the changes in PrxII expression are associated with a variety of human diseases, including cancer.Conoidin A binds to the peroxidatic cysteine of TgPrxII, inhibiting its enzymatic activity?in vitro. Conoidin A also shown to alkylate or crosslink catalytic cysteines of wild type AcePrx-1 in?Ancylostoma ceylanicum?and human PrxII and PrxIV with similar efficiency. But it is ineffective to mitochondrial hPrxIII.Conoidin A (5 μM) can inhibit the glucose oxidase-mediated hyperoxidation of mammalian peroxiredoxin I and II.
Conoidin A (intraperitoneal injection; 5?mg/kg; for three successive days before MI/R injury) blocks the effect of Luteolin (HY-N0162) on the ST‐segment elevation.?Furthermore, an increase in the infarct size presented of the MI/R group can be reduced by Luteolin. But pre‐treatment with conoidin A abolishs the effect of Luteolin. Pre‐treatment with conoidin A also prevents Luteolin-reduced activities of CK‐MB, AST and LDH in vivo .
Animal Model: | Rat myocardial I/R model |
Dosage: | 5?mg/kg |
Administration: | Intraperitoneal injection; 5?mg/kg; for three successive days before MI/R injury |
Result: | Significantly reversed the antioxidative effect of Luteolin. Impaired the protective effects of luteolin. |